Lifebit partners with Flatiron Health to accelerate cancer research

Lifebit-partners-with-Flatiron-Health-to-accelerate-cancer-research.jpg
© Getty Images (Getty Images)

Lifebit and Flatiron Health have announced a multi-year strategic partnership to support cancer research and enable scientific discoveries.

Implementing Lifebit’s pioneering federated Trusted Research Environment technology will enable approved researchers to safely and securely access data on cancer patients to enable breakthrough analysis globally.

Flatiron Health has an international presence across the United Kingdom, Germany, US and Japan and works in collaboration with hospitals and health networks to design custom approaches tailored to each country.

Health data generated by hospitals, healthcare providers, research organisations and clinical trials hold the potential to advance research and innovation, improve patient care and accelerate drug development.

The sensitivity of these data requires the utmost security and privacy measures that demonstrate strict compliance with global data use regulations to ensure patient data protection, and build patient confidence and trust in the use of their data for research.

According to Lifebit, its technology delivers this necessary security and is already in use with major initiatives including Genomics England, the Danish National Genome Center and NIHR Cambridge Biomedical Research Centre.

The new partnership will enable Flatiron and its partners to continue to support “trustworthy and secure” access to data, deliver research and innovation to develop new treatments for cancer, and improve patient care and outcomes.

“This partnership will continue to help improve treatment, care and quality of life of people with cancer," said Dr. Arun Sujenthiran, UK clinical lead and senior medical director at Flatiron Health.

“The advanced capabilities of Lifebit’s Trusted Research Environment, coupled with our focus to reimagine the infrastructure of cancer care, will enable us to unlock the potential of cancer data to support research into new therapies and help get them to patients more quickly.”

Dr. Chiara Bacchelli, precision medicine and human genetics lead at Lifebit, added: “At Lifebit we are proud to announce this important partnership with Flatiron and to demonstrate our commitment to the safe and secure use of data for research, which we know is so important for building trust and confidence amongst patients.”

“It is a privilege to enable researchers to more effectively collaborate across these rich datasets through the Lifebit platform and we are excited about the possible outcomes for cancer research.”